<DOC>
	<DOCNO>NCT02020330</DOCNO>
	<brief_summary>This randomise two arm study , compare artemether-lumefantrine 3 day 5 day treatment . Patients randomise block ten one two treatment arm . The standard regimen twice daily three day delay least eight hour first second dos . A single primaquine give patient first day treatment gametocytocidal activity . The initial treatment give supervision , subsequent dos give patient take home . Patients follow nine visit forty two day .</brief_summary>
	<brief_title>Optimising Operational Use Artemether-lumefantrine Comparing 3 Day Versus 5 Day</brief_title>
	<detailed_description>- The study conduct 6 village health centre Mon Kayin state - The patient parent/guardian ( case minor age ) must personally sign date late approve version inform consent form study specific procedure perform - A case record form complete patient documenting symptom prior clinic attendance , concomitant illness , drug history . Height , weight , vital sign physical examination finding record . - At enrolment ( D0 ) patient follow sample take : - Repeat parasite count ( thick thin film ) . Treatment start without wait result . - Filter paper blood blot ( 3 dot Whatman 3MM filter paper approx 180-300 µL blood ) parasite genotyping ( MSP1 , MSP2 , GLURP case recurrence follow-up ) - Haemoglobin - Laboratory procedure - Slide microscopy : Thick thin blood film stain Giemsa read count express number parasite per 500 white blood cell - Molecular study : The sample use detect asexual parasite ( blood smear , sensitive PCR ) , parasite population structure ( Sequenom genotyping sequence ) , gametocyte ( microscopy ) . The sample store cool box keep maximum 5 day field transport local laboratory processing . Plasma buffy coat separate , frozen store . The frozen pack red cell transport molecular laboratory MORU , Bangkok , Thailand , sample processing ( DNA extraction , quantitative PCRs ) .</detailed_description>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>1 . Age ≥ 6 year 2 . Symptomatic malaria infection , i.e . history fever presence fever &gt; 37.5°C 3 . Microscopic confirmation asexual stage P. falciparum ( may mix nonfalciparum specie ) parasitaemia PFT≥5/500 WBC 4 . Written informed consent give participate trial 1 . Pregnancy lactation ( urine test β HCG perform woman child bear age unless menstruate ) . 2 . Female 12 18 year age 3 . P. falciparum asexual stage parasitaemia great equal 4 % red blood cell ( 175,000/µL ) . 4 . Signs symptom indicative severe malaria include : Impaired consciousness ( Blantyre Coma Score &lt; 5 Glasgow Coma Scale &lt; 15 ) Severe anaemia ( Hb % &lt; 5 mg/dl ) Bleeding disorder evidence epistaxis , bleed gum , frank haematuria , bleed venepuncture sit Respiratory distress Severe jaundice Haemodynamic shock 5 . A full course artemetherlumefantrine treatment previous 28 day 6 . Known hypersensitivity artemisinins define history erythroderma/other severe cutaneous reaction , angioedema anaphylaxis 7 . History splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>falciparum , malaria</keyword>
</DOC>